157 related articles for article (PubMed ID: 38263580)
1. Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
Bando H; Yamaguchi K; Mitani S; Sawada K; Mishima S; Komine K; Okugawa Y; Hosoda W; Ebi H
Cancer Sci; 2024 Mar; 115(3):1014-1021. PubMed ID: 38263580
[TBL] [Abstract][Full Text] [Related]
2. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition.
Ebi H; Bando H; Taniguchi H; Sunakawa Y; Okugawa Y; Hatanaka Y; Hosoda W; Kumamoto K; Nakatani K; Yamazaki K
Cancer Sci; 2020 Oct; 111(10):3962-3969. PubMed ID: 32667108
[TBL] [Abstract][Full Text] [Related]
3. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition.
Yamazaki K; Taniguchi H; Yoshino T; Akagi K; Ishida H; Ebi H; Nakatani K; Muro K; Yatabe Y; Yamaguchi K; Tsuchihara K
Cancer Sci; 2018 Jun; 109(6):2074-2079. PubMed ID: 29873882
[TBL] [Abstract][Full Text] [Related]
4. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
6. Clinical Validation of Plasma-Based Genotyping for
Aoki Y; Nakamura Y; Denda T; Ohta T; Esaki T; Shiozawa M; Yamaguchi K; Yamazaki K; Sunakawa Y; Kato T; Okano N; Taniguchi H; Sato T; Oki E; Nishina T; Komatsu Y; Matsuhashi N; Goto M; Yasui H; Ohtsubo K; Moriwaki T; Takahashi N; Horita Y; Boku S; Wakabayashi M; Ikeno T; Mitani R; Yuasa M; Yoshino T
JCO Precis Oncol; 2023 Jun; 7():e2200688. PubMed ID: 37343204
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
9. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen R; Cervera P; Svrcek M; Pellat A; Dreyer C; de Gramont A; André T
Curr Treat Options Oncol; 2017 Feb; 18(2):9. PubMed ID: 28214977
[TBL] [Abstract][Full Text] [Related]
10. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
11. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
12. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.
Wang F; Huang YS; Wu HX; Wang ZX; Jin Y; Yao YC; Chen YX; Zhao Q; Chen S; He MM; Luo HY; Qiu MZ; Wang DS; Wang FH; Xu M; Li YH; Xu RH
Gut; 2022 Jul; 71(7):1340-1349. PubMed ID: 34489309
[TBL] [Abstract][Full Text] [Related]
13. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with
Masuishi T; Taniguchi H; Kotani D; Bando H; Komatsu Y; Shinozaki E; Nakajima TE; Satoh T; Nishina T; Esaki T; Wakabayashi M; Nomura S; Takahashi K; Ono H; Hirano N; Fujishiro N; Fuse N; Sato A; Ohtsu A; Yoshino T
ESMO Open; 2019; 4(6):e000590. PubMed ID: 31798981
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
Benavides M; Alcaide-Garcia J; Torres E; Gil-Calle S; Sevilla I; Wolman R; Durán G; Álvarez M; Reyna-Fortes C; Ales I; Pereda T; Robles M; Kushnir M; Odegaard J; Faull I; Alba E
ESMO Open; 2022 Jun; 7(3):100481. PubMed ID: 35525184
[TBL] [Abstract][Full Text] [Related]
16. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
[TBL] [Abstract][Full Text] [Related]
17. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
Manca P; Corallo S; Busico A; Lonardi S; Corti F; Antoniotti C; Procaccio L; Clavarezza M; Smiroldo V; Tomasello G; Murialdo R; Sartore-Bianchi A; Racca P; Pagani F; Randon G; Martinetti A; Sottotetti E; Palermo F; Perrone F; Tamborini E; Prisciandaro M; Raimondi A; Di Bartolomeo M; Morano F; Pietrantonio F
Clin Cancer Res; 2021 May; 27(9):2505-2514. PubMed ID: 33547199
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
19. [Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm].
Schneider R; Schneider C; Büttner R; Reinacher-Schick A; Tannapfel A; Fürst A; Rüschoff J; Jakobeit C; Royer-Pokora B; Möslein G
Zentralbl Chir; 2015 Dec; 140(6):591-9. PubMed ID: 25372301
[TBL] [Abstract][Full Text] [Related]
20. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
